Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2020 VISTA is the Website for LPBI Group’s Seven Health Care Contents Asset Classes prospected for technology ownership transfer and monetization

 

Our portfolio of Intellectual Property (IP) include NINE asset classes:

Asset Classes	Type	Quantity
Asset Class I	The Journal 3/3/2020 Views 1,723,051	5,742 articles on 3/3/2020     Valuation done by Joel on Alex WP Data
Asset Class II	BioMed e-Series https://pharmaceuticalintelligence.com/2019-vista/global-market-penetration-forecast-for-each-volume-in-the-16-volume-biomed-e-series/	16 volumes   Valuation done by Joel & Aviva
Asset Class III	e-Proceedings	60 events   Valuation done by Dr. Williams & Aviva
Asset Class IV	Platform, composition of methods and workflows for the content creation of scientific curations	TBD
Asset Class V	Gallery of Biological Images in use in Articles and Books	TBD
Asset Class VI	Team of Experts	FIT Bios
Asset Class VII	Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale	96K page downloads been Updated
Asset Class VIII	Subscribers to the Website	2,543
Asset Class IX	INTANGIBLE ASSETS & Intrinsic Value = Good Will	TBD

 

DETAILS about IP Asset Class I: LPBI Journal, IP Asset Class II: BioMed e-Series and IP Asset Class III: Biotech & Medical Conference e-Proceedings and Tweet Collections

 

Our VAST intellectual property (IP) portfolio includes three asset classes:

• IP Asset Class I: LPBI Journal

https://lnkd.in/eEw5q7N

1.7Million eReaders, 5700 scientific articles, 690 categories of research

• IP Asset Class II: BioMed e-Series

https://lnkd.in/ekWGNqA

16 Volumes in Medicine

What make our e-Books UNIQUE: An Example

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. Published on 12/28/2019

• No other book covers the same topics in a single volume. In terms of synergy, this book combines:
  1. Content curation in article format with embedded videos and audio podcasts
  2. Conference e-Proceedings based on real-time coverage by the authors and editors of this book.
  3. Archived tweets of quotes from speakers at leading Biotech conferences, posted in real-time by the same authors
• It integrates in a single volume four distinct perspectives: (a) basic science, (b) technologies & methodologies, (c) clinical aspects, and (d) business and legal aspects.
• The material in this book represents the scientific frontier in Biological Sciences and Medicine related to the Genomics aspects of Disease Onset. It addresses:
  1. All aspects of life: the Cell, the Organ, the Human Body and Human Populations
  2. All methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics

• Artificial Intelligence in Medicine is covered in Part 3 of the e-Book. 3.1 to 3.5 represent the frontier in this emerging field:

  3.1 The Science

  3.2 Technologies and Methodologies

  3.3 Clinical Aspects

  3.4 Business and Legal

  3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset

• No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
• No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
• No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience
• No other book has 326 articles on the topics included in the Book’s title: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

• IP Asset Class III: Biotech & Medical Conference e-Proceedings

https://lnkd.in/dc2qGAK

Corpus of 70 events covered in real time yielding 60 e-Proceedings and 36 Tweet Collections

OTHER ASSET CLASSES: IV, V, VI, VII

• Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
• Asset Class V is a Gallery of ~5000 images used in the articles and books
• Asset Class VI is the Team of Experts
• Asset Class VII are the Royalties on BioMed e-Series:

1. e-Book age down loads,
2. e-Book borrowings and
3. e-Book sale

 

Asset List showing Value:

 

@@@@@ TANGIBLE ASSETS:

1. The Journal has 1.7 Million eReaders

— It has >5700 articles 

— It demonstrates > 7500 comments by Scientists for 5700 articles 

— It has >10K tags counted by the computer

— It has 700 categories of research in SIX disciplines among them the most complex are

• Cell signaling
• ATP
• Autophage
• Computational Biology and NGS
• Cardiac imaging
• Endosome
• Liposomes

2. The BioMed e-Series 

Royalties structure:

– 96,000 to 125,000 page downloads – GLOBAL REACH

– x book borrowing

– y book sale – suppressed by Unlimited Prima Membership: READ FOR FREE and Pay per view 

– 65% of book sales are retained by Amazon

 

3. e-Proceedings and Activity on Twitter.com

•  LPBI is the One and only e-Proceedings generator at end of Conference by one click

 

• The #WMIF19 Influencers via @symplur‘s #HealthcareHashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and Ranked #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

 

• For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

 

 

@@@@@ INTANGIBLE ASSETS equal e-Reputations

 

A. Institutions following @AVIVA1950 and @ pharma_BI

• TECHNION
• WEITZMAN INSTITUTE
• HEBREW UNIV
• PARTNERS: MGH & BWH
• BROAD INSTITUTE  @MIT & @Harvard

B. Aviva is followed by 500 CEOs 200 CEOs in Biotech & Pharma on LinkedIn and

C. Aviva’s >7300 followers 1st level connection by Industry

Chemicals	2366
Pharmaceuticals	919
Biotechnology	841
Oil & Energy	664
Staffing and Recruiting	218
Management Consulting	218
Research	207
Information Technology and Services	198
Environmental Services	183
Plastics	171
Food & Beverages	137
Marketing and Advertising	115
Human Resources	96
Food Production	93
Financial Services	92

D. Aviva is bestowed by >1000 endorsements 

@@@@ LPBI Group’s Social Media Presence in 2020

 

Our Social Media Presence in 2020 is by two handles on Twitter.com

 

@pharma_BI 

• Official handle of my Venture: Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, NJ, Salt Lake City, Berkeley, Cambridge UK, Maine, New Delhi, Palo Alto, Philadelphia, Toronto, Newark, DE

 

@AVIVA1950

• Personal account of Aviva Lev-Ari, PhD, RN https://lnkd.in/eEyn69r – LPBI Group’s Founder

 

@AVIVA1950

 

2019 World Medical Innovation Forum on AI in Medicine – Aviva’s rankings as Influencer

• The #WMIF19 Influencers via @symplur‘s #HealthcareHashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

 

• For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets

 

• The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

 

• Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019

 

• Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers

 

• Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN

 

• The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

 

@pharma_BI

 

• LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019

 

• MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by

 

• Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019

 

Follow the links

1. Executive Summary
2. Opportunities Map in the Acquisition Arena
3. Dynamic Contents for LPBI Group’s PowerPoint Presentation
4. Detailed Technology Description
5. Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
6. Top Authors by Number of eReaders Views
7. Top Articles by Number of e-Readers for All Days ending 2019-02-17
8. LPBI Group’s Social Media Presence
9. Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
10. Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
11. Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
12. Financial Advisory & Legal Advisory Providers: US & Israel
13. Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
14. FIT Members Contribute to Opportunities Map
15. FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
16. Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
17. LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
18. FIT members – Who works on WHAT?
19. Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
20. MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
21. JOURNAL Statistics on 2/24/2019
22. Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
23. Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
24. REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
25. 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 
26. Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
27. Summer 2019 Plan – Research Associates Tasks
28. LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
29. WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
30. For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
31. The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
32. e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW

 

Our Team

• Aviva Lev-Ari, PhD, RN, Director and Founder
• Members of the Board
• Senior Editors
• Experts, Authors, Writers (EAWs)
• Business Development & Private Equity Investment
• Scientific Delegation Members & Patent Holders
• Inventors: Biologics
• Inventors: Medical Devices
• Research Assistants
• Research Associates

This page has the following sub pages.

• e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW 
• Executive Summary
• Opportunities Map in the Acquisition Arena
• Dynamic Contents for LPBI Group’s PowerPoint Presentation
• Detailed Technology Description
• Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
• Top Authors by Number of e-Readers Views
• Top Articles by Number of e-Readers for All Days ending 2019-02-17
• LPBI Group’s Social Media Presence
• Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
• Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
• Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 
• Financial Advisory & Legal Advisory Providers: US & Israel
• Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
• Final Improvement Team (FIT) Members Contribute to Opportunities Map & Define LPBI Uniqueness
• FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lasping of Active Status, COMPs Formulas
• HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
• LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
• Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
• MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
• FIT members – Who works on WHAT?
• JOURNAL Statistics from Inception, Data retrieved on 2/24/2019
• Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
• Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
• REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
• 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 
• Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
• Summer 2020 Plan – Research Associates Tasks
• LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
• WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019